Skip to content
OpenCapital
Get started

Prelude Therapeutics PRLD Q4 2025 Annual earnings

Reported March 10, 2026 · Before market open

Revenue$5.6MMiss by $14.9MDiluted EPS-$0.20Beat by $0.13
Revenue estimate$20.5M
EPS estimate-$0.33

Next report

Aug 13, 2026 (in a month)
Revenue estimate$4.8M
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$4.6MIn line
Q4 2025$5.6MMiss by $14.9M
Q3 2025$6.5MMiss by $14.0MQ4 2024$4.0M

Diluted EPS

Q1 2026-$0.13Beat by $0.14
Q4 2025-$0.20Beat by $0.13
Q3 2025-$0.26Beat by $0.09Q2 2025-$0.41Beat by $0.04Q1 2025-$0.42Beat by $0.05Q4 2024-$0.38Beat by $0.11

Ask the moment Prelude Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Prelude Therapeutics report Q4 2025 earnings?
Prelude Therapeutics (PRLD) reported Q4 2025 earnings on March 10, 2026 before market open.
What were Prelude Therapeutics's Q4 2025 revenue and EPS?
Prelude Therapeutics reported revenue of $5.6M and diluted EPS of $-0.20 for Q4 2025.
Did Prelude Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $20.5M by $14.9M. EPS beat the consensus estimate of $-0.33 by $0.13.
How did Prelude Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 40.0% from $4.0M a year earlier and diluted EPS grew 47.4% from $-0.38.
Where can I find Prelude Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-099424) and the 10-K periodic report (0001193125-26-099428) directly on SEC EDGAR. The filing index links above go to sec.gov.